Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLM | Q9NP87 | 2/20 | 0.63 |
| ▸ | POLK | Q9UBT6 | 2/20 | 0.63 |
| ▸ | POLL | Q9UGP5 | 2/20 | 0.63 |
| ▸ | POLH | Q9Y253 | 2/20 | 0.63 |
| ▸ | TOP1 | P11387 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | CDC25B | P30305 | 2/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | CASP7 | P55210 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10395154 | 0.84 | POLM (0.63) | POLMPOLKPOLLPOLHTOP1 | |
| SCHEMBL10394363 | 0.84 | POLM (0.63) | POLMPOLKPOLLPOLHTOP1 | |
| SCHEMBL7911252 | 0.82 | POLM (0.67) | POLMPOLKPOLLPOLHTOP1 | |
| SCHEMBL1287104 | 0.79 | TOP1 (0.65) | POLMPOLKPOLLPOLHTOP1 | |
| SCHEMBL6662940 | 0.78 | TOP1 (0.60) | POLMPOLKPOLLPOLHTOP1 | |
| SCHEMBL12827331 | 0.75 | TOP1 (1.00) | POLMPOLKPOLLPOLHTOP1 | |
| SCHEMBL9006672 | 0.74 | TOP1 (0.59) | POLMPOLKPOLLPOLHTOP1 | |
| SCHEMBL5821897 | 0.72 | TOP1 (0.76) | POLMPOLKPOLLPOLHTOP1 | |
| SCHEMBL5817354 | 0.71 | TOP1 (0.53) | POLMPOLKPOLLPOLHTOP1 | |
| SCHEMBL3414850 | 0.71 | TOP1 (1.00) | POLMPOLKPOLLPOLHTOP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6214969-B1 | MODIFIED DECAPEPTPIDE; ANTITUMOR AGENTS; ANTICARCINOGENIC AGENTS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | 2001-04-10 | — | — | US | claimed |
| WO-1992022322-A1 | LHRH ANALOGS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 1992-12-23 | — | — | WO | claimed |
| EP-0450461-A2 | LHRH Analogs | The Administrators of The Tulane Educational Fund (US) | 1991-10-09 | — | — | EP | claimed |
| EP-0450480-A2 | Somatostatin Analogues | The Administrators of The Tulane Educational Fund (US) | 1991-10-09 | — | — | EP | claimed |
| US-20200339990-A1 | RNAi CONJUGATES, PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2020-10-29 | — | — | US | disclosed |
| EP-3454908-A1 | TARGETED CONSTRUCTS AND FORMULATIONS THEREOF | Tarveda Therapeutics, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| WO-2018222987-A1 | TARGETED CONSTRUCTS | TARVEDA THERAPEUTICS, INC. (US) | 2018-12-06 | — | — | WO | disclosed |
| US-20180296685-A1 | TARGETED CONSTRUCTS AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2018-10-18 | — | — | US | disclosed |
| US-20180273948-A1 | RNAi CONJUGATES, PARTICLES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2018-09-27 | — | — | US | disclosed |
| US-20180258411-A1 | COMPOSITIONS AND METHODS FOR GENOME EDITING | TVA (ABC), LLC | 2018-09-13 | — | — | US | disclosed |
| EP-3353309-A1 | COMPOSITIONS AND METHODS FOR GENOME EDITING | Tarveda Therapeutics, Inc. (US) | 2018-08-01 | — | — | EP | disclosed |
| WO-2017210246-A2 | PENICILLAMINE CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
| US-6214969-B1 | MODIFIED DECAPEPTPIDE; ANTITUMOR AGENTS; ANTICARCINOGENIC AGENTS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | 2001-04-10 | — | — | US | disclosed |
| US-6214969-B1 | MODIFIED DECAPEPTPIDE; ANTITUMOR AGENTS; ANTICARCINOGENIC AGENTS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | 2001-04-10 | — | — | US | disclosed |
| WO-1992022322-A1 | LHRH ANALOGS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 1992-12-23 | — | — | WO | disclosed |
| WO-1992022322-A1 | LHRH ANALOGS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 1992-12-23 | — | — | WO | disclosed |
| EP-0450480-A2 | Somatostatin Analogues | The Administrators of The Tulane Educational Fund (US) | 1991-10-09 | — | — | EP | disclosed |
| EP-0450480-A2 | Somatostatin Analogues | The Administrators of The Tulane Educational Fund (US) | 1991-10-09 | — | — | EP | disclosed |
| EP-0450461-A2 | LHRH Analogs | The Administrators of The Tulane Educational Fund (US) | 1991-10-09 | — | — | EP | disclosed |
| EP-0450461-A2 | LHRH Analogs | The Administrators of The Tulane Educational Fund (US) | 1991-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180296685-A1 | TARGETED CONSTRUCTS AND FORMULATIONS THEREOF | PAICS, SEPTIN8, SEPTIN7 | POLM 136/4885POLK 2614/4885POLL 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.